In some common cardiovascular outcome trials (CVOTs) such as the dapagliflozin effect on cardiovascular events led by the 'Thrombolysis in Myocardial Infarction' study group (DECLARE-TIMI 58), empagliflozin cardiovascular outcome event trial in Type 2 diabetes mellitus patients removing excess glucose (EMPA-REG), and the canagliflozin cardiovascular assessment study (CANVAS), SGLT2 inhibitors showed protective cardio-renal capabilities in diabetic patients with heart failure, CKD, and cardiovascular risk factors [4-7]. This evidence concerns the gene SLC5A2 and chronic kidney disease.